Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine + trazodone for obstructive sleep apnea
IRCT20220607055095N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atomoxetine and trazodone in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Tehran University of Medical Sciences. Primary endpoints: Improve sleep quality and reduce sleep apnea and hypopnea attacks, Number of respiratory arrests and 1 more. Started Jul 2023; status: completed.
02
Drugs
atomoxetinetrazodone
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on IRCT20220607055095N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220607055095N2.